Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2022-07-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Xiamen Aide Bio-Pharmaceutical Technology Co., Ltd. It reports the approval of the 2022 semi-annual report and its summary by the board of directors. The document includes details about the meeting date, attendance, and voting results. It states that the full semi-annual report and summary are available on the designated disclosure website, indicating this document itself is not the full report but an announcement of the board's approval of the interim report. Given the document length (677 characters) and content, it is not the full interim report but a meeting resolution announcement related to the interim report. This fits best under the category of Board/Management Information (MANG), as it announces board decisions and approvals rather than providing the full financial report or a simple publication notice. Therefore, the classification is MANG with high confidence.
2022-07-29 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, prices, compliance with regulations, and future intentions to continue the buyback. It does not contain financial statements or earnings data but focuses on the company's transaction in its own shares. The document length is short (1319 characters) and is clearly an announcement of share repurchase progress, fitting the category of Transaction in Own Shares (POS).
2022-07-04 Chinese
2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2022 first extraordinary general meeting of shareholders of Xiamen Aide Biomedical Technology Co., Ltd. It details the meeting date, attendance, voting results on specific proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results and procedural compliance of a shareholders' meeting. It does not contain financial statements, management discussion, or detailed report content. The document length is short (2148 characters) and is clearly an announcement of voting results from a shareholders meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-06-20 Chinese
2022年第一次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and compliance of the convening, holding, attendance, and voting procedures of the 2022 first extraordinary general meeting (临时股东大会) of Xiamen Aide Biomedical Technology Co., Ltd. It details the verification of the meeting's procedures, attendees' qualifications, and voting results. The document does not contain financial statements or performance data, nor is it a report of financial results or management discussion. It is a legal opinion related to a shareholders' meeting, specifically focusing on the voting results and procedural legality. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document length is under 5,000 characters, but it is not merely an announcement of a report; it is the legal opinion on the voting results themselves. Therefore, the appropriate classification is DVA with high confidence.
2022-06-20 Chinese
关于取得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement about the company obtaining an invention patent certificate. It includes details about the patent and its implications for the company. There is no financial data, no mention of financial results, no regulatory filings, or meeting materials. The document is an announcement of a patent grant, which does not fit into financial report categories. It is a regulatory announcement related to intellectual property. Given the content and length, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2022-06-17 Chinese
公司章程（2022年6月）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 厦门艾德生物医药科技股份有限公司 dated June 2022. It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, share issuance, share transfer, shareholder meetings, and other governance-related rules. There is no indication that this is an annual report, financial report, or announcement of voting results. Instead, it is a governance document that sets out the internal rules and regulations of the company. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not just an announcement or summary.
2022-06-02 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.